FDA Medical Devices Brief

Headline

Nova Biomedical initiates global correction for StatStrip Gen 2.0 glucose meter over patient ID software flaw

Executive Summary

Nova Biomedical initiated a voluntary global Medical Device Correction on July 24, 2026 for the StatStrip Glucose Hospital Meter System Gen 2.0. A software defect may cause glucose results to be linked to the wrong patient's medical record. One adverse event involving inappropriate insulin administration has already been reported in the U.S.

Nova Biomedical announced the correction publicly on October 5, 2026.

Bottom Line

A shipment hold on affected devices is in place. Nova recommends interim manual verification steps for facilities continuing to use the device and advises switching to an alternative device where one is available. Cresthaven reading: hospital pharmacy, nursing, and biomedical engineering teams operating Gen 2.0 StatStrip meters face an active patient-safety exposure during the period before the planned November 2026 software update, with manual verification, recommended software configurations, and alternative devices as the interim controls.

Key Regulatory Signals

• Scope Limited to Gen 2.0 Model: The correction applies to all serial numbers of the Gen 2.0 StatStrip Glucose Hospital Meter System across six part numbers distributed in the U.S. and globally. Prior models, designated Gen 1.0, Gen 1.75, Gen 1.86, and Gen 1.87, are not affected.
• Patient Safety Risk From Misassigned Results: When a patient ID barcode is scanned, prior patient information may remain on the meter screen. If accepted without verification, glucose results may be recorded in the wrong patient's medical record, potentially leading to delayed treatment, unnecessary treatment including inappropriate insulin administration, or failure to treat the intended patient.
• One Adverse Event Reported Before Correction Initiation: Nova Biomedical received one U.S. adverse event report on July 17, 2026, involving inappropriate insulin administration based on another patient's glucose results. No serious adverse events related to this issue have been reported.
• Shipment Hold in Place; Software Update Planned for November 2026: Nova has implemented a shipment hold on all affected StatStrip Glucose Hospital Meter Systems while corrective actions are being developed and validated. Nova intends to roll out a software update in November 2026 in a phased manner. Cresthaven reading: facilities currently using Gen 2.0 devices face an interim period during which manual verification steps and the recommended software configurations are the available mitigations.
• Interim Verification Steps Recommended for Current Users: Nova recommends that after every barcode scan, healthcare providers verify the patient ID, name, date of birth, and other identifying information on the Confirm Patient ID screen before accepting results, and verify again when the glucose result populates. Nova also recommends use of patient validation and operator log-off software configurations available in the current system and NovaNet middleware.
• Device Replacement Advised Where Alternatives Exist: Nova advises that if an alternative device is available, users should stop using the affected device. Where no alternative exists, Nova states users must continue to follow the interim mitigation steps until the software fix becomes available.

Regulatory Delta

• Nova Biomedical characterizes this action as a global Medical Device Correction initiated July 24, 2026. No FDA-classified recall tier is assigned in this release. - The underlying risk is software-origin: patient ID misassignment in a point-of-care glucose monitoring setting, with one adverse event already on record prior to the correction. - The FDA posted this announcement as a public service under its standard protocol for company-initiated corrections, without endorsing the product or company.

Materiality Classification

MEDIUM — A voluntary global Medical Device Correction affecting all Gen 2.0 StatStrip Glucose Hospital Meter System serial numbers across U.S. and international distribution, with one pre-correction adverse event on record and a patient-safety risk that requires active interim response from all facilities using the affected model.

Intelligence Outlook

Monitor the FDA safety recalls and alerts page and the Nova Biomedical correction notice for confirmation of the November 2026 software update release and any change in the scope or classification of this correction.